Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

NCT03881488 is registered in ClinicalTrials.gov with Compass Therapeutics as lead sponsor.

NCT NCT03881488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03881488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
Lead sponsor
Compass Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
May 17, 2019
Completion date
May 21, 2025
Enrollment
100 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, locally advanced solid tumor, melanoma, mesothelioma, metastatic cancer, non-small cell lung cancer, small cell lung cancer